Welcome to the November 2022 edition of the HealthTech Activator (HTA) Monthly Wrap.
In this month’s HTA blog we discuss Callaghan Innovation’s wider product portfolio, focusing on how the Tech Incubator programme is proving a success with startups developing tech with human health applications.
The HTA is running a new webinar covering Global Trends in Health Technology Assessment on December 9th. There are only a few spaces left for this event, you can read more and register below. We look forward to seeing you online!
Read on for links to sector news from the past month, and if you have any comments or suggestions to improve our newsletter, we would love to hear from you! As always, thanks for subscribing to the HTA.
HTA news
Supporting Healthtech Success: Callaghan Innovation and Tech Incubators
HTA Team
Apart from the HTA, Callaghan Innovation has several products and services that are relevant to healthtech companies looking for support on their journey. In this month’s blog, the HTA team introduces Callaghan Innovation’s wider product portfolio and explores the Tech Incubator programme in greater detail.
Global Trends in Health Technology Assessment Webinar
9 December, Online | Presented by Thomas Paulsson
We are looking forward to our next HealthTech Activator (HTA) webinar - Global Trends in Health Technology Assessment - coming up on December 9th.
This webinar will provide participants with an overview of some of the approaches used by decision makers in key markets to evaluate novel health technologies, and reviews some of the trends that healthtech companies should be aware of.
Spaces are limited for this live webinar, so register early via the button below if you’d like to attend.
NZ-based startups in the aged care and digital health space can apply for the AWS Healthcare Accelerator before 11 December, delivered in collaboration with ANDHealth (8 November: ANDHealth).
Richard Little was interviewed about his journey as a healthtech entrepreneur, from founding Rex Bionics through to his current work with Exsurgo (14 November: NZ Business).
Scentian Bio has received a US$1.7m grant from the Bill & Melinda Gates Foundation for development of diagnostic applications of its biosensor platform (17 November: NZ Entrepreneur).
Cawthron Institute scientists have developed a scalable algae-derived neosaxitoxin-based local anaesthetic with successful phase 1 trials in the US and Europe (27 November: RNZ).
